- Home
- BUJA vs EYEN Comparison
BUJA vs EYEN Comparison
Compare BUJA & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- EYEN
- Stock Information
- Founded
- BUJA 2022
- EYEN 2014
- Country
- BUJA Malaysia
- EYEN United States
- Employees
- BUJA N/A
- EYEN N/A
- Industry
- BUJA Blank Checks
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- EYEN Health Care
- Exchange
- BUJA Nasdaq
- EYEN Nasdaq
- Market Cap
- BUJA N/A
- EYEN 38.2M
- IPO Year
- BUJA 2023
- EYEN 2018
- Fundamental
- Price
- BUJA $10.96
- EYEN $0.55
- Analyst Decision
- BUJA
- EYEN Strong Buy
- Analyst Count
- BUJA 0
- EYEN 2
- Target Price
- BUJA N/A
- EYEN $12.00
- AVG Volume (30 Days)
- BUJA 2.7K
- EYEN 879.0K
- Earning Date
- BUJA 01-01-0001
- EYEN 11-11-2024
- Dividend Yield
- BUJA N/A
- EYEN N/A
- EPS Growth
- BUJA N/A
- EYEN N/A
- EPS
- BUJA 0.29
- EYEN N/A
- Revenue
- BUJA N/A
- EYEN $31,405.00
- Revenue This Year
- BUJA N/A
- EYEN $50,309.30
- Revenue Next Year
- BUJA N/A
- EYEN $421.63
- P/E Ratio
- BUJA $37.13
- EYEN N/A
- Revenue Growth
- BUJA N/A
- EYEN N/A
- 52 Week Low
- BUJA $10.30
- EYEN $0.37
- 52 Week High
- BUJA $12.18
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- EYEN 52.60
- Support Level
- BUJA $10.85
- EYEN $0.52
- Resistance Level
- BUJA $10.85
- EYEN $0.59
- Average True Range (ATR)
- BUJA 0.00
- EYEN 0.05
- MACD
- BUJA -0.00
- EYEN 0.01
- Stochastic Oscillator
- BUJA 87.50
- EYEN 66.45
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.